Basic Information
ABSTRAL SUBLINGUAL TABLET 200 mcg
TABLET
Regulatory Information
SIN15148P
January 6, 2017
Prescription Only
Therapeutic
SUBLINGUAL
August 10, 2023
June 3, 2025
XN02AB03
Company Information
Active Ingredients
Strength: 200 µg
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Patients without maintenance opioid therapy as there is an increased risk of respiratory depression. Severe respiratory depression or severe obstructive lung conditions. Treatment of acute pain other than breakthrough pain. Patients being treated with medicinal products containing sodium oxybate.
Indication Information
**4.1 Therapeutic indications** Management of breakthrough pain in adult patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.